Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.53 |
| ▸ | ASIC3 | Q9UHC3 | 2/20 | 0.48 |
| ▸ | GSK3A | P49840 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | FLT3 | P36888 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21568765 | 0.85 | LDHA (0.57) | LDHAASIC3GSK3AGSK3BNPC1 | |
| SCHEMBL29507311 | 0.82 | LDHA (0.62) | LDHAASIC3GSK3AGSK3BNPC1 | |
| SCHEMBL2481915 | 0.82 | LDHA (0.62) | LDHAASIC3GSK3AGSK3BNPC1 | |
| SCHEMBL28784756 | 0.82 | ASIC3 (0.53) | LDHAASIC3GSK3AGSK3BNPC1 | |
| SCHEMBL458363 | 0.81 | ADORA2A (0.46) | NPC1RAB9ASMN1; SMN2ADORA2AADORA1 | |
| SCHEMBL458804 | 0.81 | CYP3A4 (0.47) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL30480541 | 0.80 | LDHA (0.56) | LDHAASIC3GSK3AGSK3BNPC1 | |
| SCHEMBL13299607 | 0.80 | LDHA (0.56) | LDHAASIC3GSK3AGSK3BNPC1 | |
| SCHEMBL19454849 | 0.78 | LDHA (0.59) | LDHAASIC3NPC1RAB9APDGFRB | |
| SCHEMBL28610327 | 0.78 | NPC1 (0.51) | LDHAASIC3GSK3AGSK3BNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113105475-B | Inhibitors of bruton's tyrosine kinase and methods of use thereof | 詹森药业有限公司 | 2022-09-09 | — | — | CN | disclosed |
| CN-113105475-A | Inhibitors of bruton's tyrosine kinase and methods of use thereof | 詹森药业有限公司 | 2021-07-13 | — | — | CN | disclosed |
| US-10822348-B2 | Inhibitors of Bruton's tyrosine kinase and methods of their use | JANSSEN PHARMACEUTICA NV (BE) | 2020-11-03 | — | — | US | disclosed |
| US-10800792-B2 | Inhibitors of Bruton's tyrosine kinase and method of their use | JANSSEN PHARMACEUTICA NV (BE) | 2020-10-13 | — | — | US | disclosed |
| US-10689396-B2 | Inhibitors of Bruton's tyrosine kinase and methods of their use | JANSSEN PHARMACEUTICA NV (BE) | 2020-06-23 | — | — | US | disclosed |
| US-20190284203-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2019-09-19 | — | — | US | disclosed |
| US-20190284204-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2019-09-19 | — | — | US | disclosed |
| CN-109071563-A | Inhibitors of bruton's tyrosine kinase and methods of use thereof | 詹森药业有限公司 | 2018-12-21 | — | — | CN | disclosed |
| EP-3386992-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE | Janssen Pharmaceutica, N.V. (BE) | 2018-10-17 | — | — | EP | disclosed |
| WO-2018103058-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2018-06-14 | — | — | WO | disclosed |
| US-7345054-B2 | Heterocyclic inhibitors of ERK2 and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-03-18 | — | — | US | disclosed |
| US-7345054-B2 | Heterocyclic inhibitors of ERK2 and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-03-18 | — | — | US | disclosed |
| US-7345054-B2 | Heterocyclic inhibitors of ERK2 and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-03-18 | — | — | US | disclosed |
| US-7304061-B2 | Heterocyclic inhibitors of ERK2 and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-12-04 | — | — | US | disclosed |
| US-7304061-B2 | Heterocyclic inhibitors of ERK2 and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-12-04 | — | — | US | disclosed |
| US-7304061-B2 | Heterocyclic inhibitors of ERK2 and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-12-04 | — | — | US | disclosed |
| US-20050234059-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2005-10-20 | — | — | US | disclosed |
| EP-1506189-A1 | PYRROLE DERIVATIVES AS INHIBITORS OF ERK2 AND USES THEREOF | Vertex Pharmaceuticals Incorporated (US) | 2005-02-16 | — | — | EP | disclosed |
| US-20040029857-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2004-02-12 | — | — | US | disclosed |
| WO-2003091246-A1 | PYRROLE DERIVATIVES AS INHIBITORS OF ERK2 AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10689396-B2 | Inhibitors of Bruton's tyrosine kinase and methods of their use | ABL1, BTK, MYLK2 | LDHA 2846/4885ASIC3 4303/4885GSK3A 271/4885 |
| US-20190284204-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE | ABL1, BTK, MYLK2 | LDHA 3072/4885ASIC3 4269/4885GSK3A 216/4885 |
| US-20050234059-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | CDK2, MAPK3, CDK1 | LDHA 4596/4885ASIC3 3715/4885GSK3A 43/4885 |
| US-10822348-B2 | Inhibitors of Bruton's tyrosine kinase and methods of their use | ABL1, BTK, MYLK2 | LDHA 2846/4885ASIC3 4303/4885GSK3A 271/4885 |
| US-20190284203-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE | ABL1, BTK, MYLK2 | LDHA 3072/4885ASIC3 4269/4885GSK3A 216/4885 |
| US-20040029857-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | CDK2, CDK1, CDK3 | LDHA 4077/4885ASIC3 3977/4885GSK3A 6/4885 |
| US-10800792-B2 | Inhibitors of Bruton's tyrosine kinase and method of their use | ABL1, BTK, MYLK2 | LDHA 3072/4885ASIC3 4269/4885GSK3A 216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.